Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 2389 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency
Osamu Saiki¹, Hiroshi Uda¹, Ayumi Matsumoto², Aya Mizumoto³, Tamaki Harada³ and Toshirou Takama³, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Higashiosaka City General Hospital, Higashiosaka, Japan, ³Nephrology, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: In AA amyloidosis patients with RA taking oral medicines such as methotrexate and prednisolone, it is generally accepted that the renal function deteriorates gradually…
Abstract Number: 2390 • 2013 ACR/ARHP Annual Meeting
Low Dose Of Tocilizumab Can Be Effective In RA Patients Who Achieve Remission.
Cecilia Prieto- Candau¹, Virginia Moreira- Navarrete², Carmen Vargas-Lebrón², Juan M Prieto-Martinez², Dolores Ruiz-Montesinos², Javier Toyos-Saenz de Miera² and Federico Navarro-Sarabia³, ¹Rheumatology, Hospital Virgen Macarena, SEVILLE, Spain, ²Rheumatology, Hospital Virgen Macarena, Seville, Spain, ³Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain
Background/Purpose: Tocilizumab (TCZ), an anti-IL-6-receptor antibody, is used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults with inadequate response or intolerance…
Abstract Number: 1762 • 2012 ACR/ARHP Annual Meeting
IL-6 Receptor Inhibition by Tocilizumab Modulates Double Negative (CD19+IgD-CD27-) B Cells in RA
Zafar Mahmood¹, Khalid Muhammad¹, Petra Roll², Stefan Kleinert³, Thomas Dörner⁴ and Hans Peter Tony⁵, ¹Department of Medicine II, Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Department of Medicine II, Rheumatology/Clinical immunology, University of Würzburg, Würzburg, Germany, ³Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ⁴CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵Rheumatology/Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose: Double negative (CD19+IgD-CD27-) B cells have been reported to be part of human memory B cell compartment. Detailed studies of DN B cells in…
Abstract Number: 1336 • 2012 ACR/ARHP Annual Meeting
Changes in the Levels of Anti-Cyclic Citrullinated Protein Antibody and Immunoglobulins in Rheumatoid Arthritis Patients After Administration of Tocilizumab
Masao Sato¹, Masao Takemura², Ryuki Shinohe³, Tsuneo Watanabe² and Katsuji Shimizu³, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Orthopaedic Surgery, Gifu University, Gifu, Japan
Background/Purpose: The recently established scoring system of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) early arthritis diagnosis criteria have assigned scores of 0, 1,…
Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Anne C. Bay-Jensen¹, Inger Byrjalsen², Andrew Kenwright³, Thierry Sornasse⁴, Claus Christiansen⁵ and Morten Asser Karsdal⁶, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³Roche, Welwyn Garden City, United Kingdom, ⁴Genentech, South San Francisco, ⁵CCBR, Ballerup, Denmark, ⁶Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
Abstract Number: 1333 • 2012 ACR/ARHP Annual Meeting
The Predictive Value of CD64 Counts for Infectious Disease in Patients Treated with Tocilizumab On the Infectious Disease Risk Management Cohort (ACT4U-study)
Atsushi Ihata¹, Hiroyuki Hagiyama², Shouhei Nagaoka³, Junichi Obata⁴, Kiyomitsu Miyachi⁵, Hidehiro Yamada⁶, Shunsei Hirohata⁷, Norihiko Koido⁸, Masaomi Yamasaki⁹, Kenichi Miyagi¹⁰, Shigeru Ohno¹¹, Daiga Kishimoto¹, Reikou Watanabe¹, Takeaki Uehara¹², Kaoru Takase¹, Maasa Hama¹, Ryusuke Yoshimi¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ³Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ⁴Hikarichuo Clinic, Kawasaki, Japan, ⁵Keigu Clinic, Kawasaki, Japan, ⁶Internal Medicine, St. Marianna University, Kawasaki, Japan, ⁷Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁸Kawasaki Rheumatism & Internal Medecine Clinic, Kawasaki, ⁹Internal Medicine, St Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan, ¹⁰Miyagi Naika Clinic, Yokohama, ¹¹Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ¹²Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan
Background/Purpose: An administration of tocilizumab (TCZ) rapidly suppresses inflammatory markers such as CRP and ESR, which makes the diagnosis of infection difficult. There is a…
Abstract Number: 1335 • 2012 ACR/ARHP Annual Meeting
Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy
Patrick Durez¹, Geneviève Depresseux², Marie Avaux², Adrien Nzeusseu Toukap³, Bernard Lauwerys³, Laurent Meric de Bellefon², Maria S. Stoenoiu² and Frédéric A. Houssiau⁴, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ³Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ⁴Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Tocilizumab (TCZ), as monotherapy and in combination with methotrexate (MTX), has been shown to be efficacious for rheumatoid arthritis patients with insufficient response to…
Abstract Number: 1281 • 2012 ACR/ARHP Annual Meeting
IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis
Masayasu Kitano¹, Sachie Kitano¹, Chieri Sato¹, Kazuyuki Fujita¹, Takahiro Yoshikawa¹, Yuki Katashima¹, Masahiro Sekiguchi¹, Naoto Azuma¹, Naoaki Hashimoto, Shinichiro Tsunoda¹, Kiyoshi Matsui¹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan
Background/Purpose: Tocilizumab (TCZ) is a humanized monoclonal anti-IL-6 receptor antibody. TCZ has demonstrated efficacy in moderate to severe active rheumatoid arthritis (RA) with inadequate clinical…
Abstract Number: 1243 • 2012 ACR/ARHP Annual Meeting
Effect of Tocilizumab Treatment On Regional Left Ventricular Function, As Assessed by Cardiac Magnetic Resonance Imaging, in Rheumatoid Arthritis Patients without Cardiac Symptoms
Hitomi Kobayashi¹, Isamu Yokoe², Hiroshi Sato¹ and Yasuyuki Kobayashi³, ¹Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ²Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of congestive heart failure, possibly via shared mechanisms of inflammation. This study was undertaken to…
Abstract Number: 1178 • 2012 ACR/ARHP Annual Meeting
IL-6 and IL-21 in Rheumatoid Arthritis
Gustavo Carbone¹, Augusta Wilson¹, Sean Diehl², Janice Bunn³, Sheldon Cooper⁴ and Mercedes Rincon⁵, ¹Rheum & Clinical Imm Unit, University of Vermont College of Medicine, Burlington, VT, ²Immunobiology, University of Vermont College of Medicine, ³Mathematics and Statistics, University of Vermont, Burlington, VT, ⁴Rheum & Clinical Imm Unit, Univ Vermont College of Med, Burlington, VT, ⁵Immunobiology, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces…
Abstract Number: 461 • 2012 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study
J.V. Tovar Beltrán¹, M.A. Guzmán Úbeda², I. Mateo Bernardo³, Rosario García-Vicuña⁴, M. Rodríguez-Gómez⁵, M. Belmonte-Serrano⁶, C. Marras⁷, E. Loza Cortina⁸, E. Pérez Pampin⁹, V. Vila Fayos¹⁰, A.B. Romero Silva¹¹ and A. Balsa¹², ¹Hospital General Universitario de Elche, Alicante, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario La Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁶Hospital General de Castellón, Castellón, Spain, ⁷Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁸Hospital de Navarra, Navarra, Spain, ⁹Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰Hospital Comarcal de Vinaroz, Castellón, Spain, ¹¹Roche Farma, Madrid, Spain, ¹²Rheumatology, Hospital La Paz, Madrid, Spain
Background/Purpose: Currently, the available evidence about tocilizumab (TCZ) use for the treatment of rheumatoid arthritis (RA) in daily clinical practice is scarce. This study was…
Abstract Number: 2548 • 2012 ACR/ARHP Annual Meeting
Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients
Julie Ducreux¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez³ and Bernard Lauwerys³, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we…
Abstract Number: 431 • 2012 ACR/ARHP Annual Meeting
Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA
Kazuyuki Yoshizaki, Prabha Tiwari, Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei Nishikawa-Matsumura, Tomoyasu Isobe and Soken-Nakazawa J. Song, Osaka University, Osaka, Japan
Background/Purpose: Cytokine-induced hepatic serum amyloid A (SAA) is associated with the pathogenesis of AA amylodosis, a fatal disease with deposition of AA amyloid fibril on…
Abstract Number: 2550 • 2012 ACR/ARHP Annual Meeting
Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study
Maxime Dougados¹, Karsten Kissel², Philip G. Conaghan³, Emilio Martin-Mola⁴, Georg A. Schett⁵, Howard Amital⁶, Ricardo M. Xavier⁷, OM Troum⁸, Corrado Bernasconi⁹ and T.W.J. Huizinga¹⁰, ¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³University of Leeds, Leeds, United Kingdom, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁸Medicine, USC Keck School of Medicine, Santa Monica, CA, ⁹Consultant, Basel, Switzerland, ¹⁰Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: 24-week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO]) in MTX-IR patients…
Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Noriko Kuwaba⁴ and Hiroyuki Ohta⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁵Medical Research, hiroshima clinic, Hiroshima, Japan
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].